Estradiol valerate/prasterone enanthate

{{Short description|Combination drug}}

{{Drugbox

| image = Estradiol valerate.svg

| width = 250px

| caption =

| image2 = Prasterone enanthate.svg

| width2 = 250px

| caption2 = Estradiol valerate (top) and
prasterone enanthate (bottom)

| type = combo

| drug_name = Estradiol valerate /
prasterone enanthate

| component1 = Estradiol valerate

| class1 = Estrogen

| component2 = Prasterone enanthate

| class2 = Androgen; Estrogen; Neurosteroid

| tradename = Gynodian Depot, Binodian Depot, Cidodian Depot, Klimax, Supligol NF

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Intramuscular injection

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 979-32-8

| CAS_number2_Ref = {{cascite|correct|CAS}}

| CAS_number2 = 23983-43-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = OKG364O896

| UNII2_Ref = {{fdacite|correct|FDA}}

| UNII2 = 2W8I1S6T5L

| ATC_prefix =

| ATC_suffix =

| PubChem = 56841030

| DrugBank =

| synonyms = EV/DHEA-E; EV/PE; SH-70833-D

}}

Estradiol valerate/prasterone enanthate (EV/DHEA-E), sold under the brand name Gynodian Depot among others, is an injectable combination medication of estradiol valerate (EV), an estrogen, and prasterone enanthate ({{abbr|DHEA|dehydroepiandrosterone}}-E), an androgen, estrogen, and neurosteroid, which is used in menopausal hormone therapy for women.{{cite web |url=https://compendium.ch/FrmMainMonographie.aspx?Id=4a7e55ac-b11f-4d80-96d0-b468ab0eb4e3&lang=de&MonType=fi&start=1 |title=Gynodian® Depot | date = May 2017 | language = de | publisher = Bayer (Schweiz) AG | location= Zürich | via = compendium.ch |access-date=15 January 2022 |archive-url=https://web.archive.org/web/20190529041314/https://compendium.ch/FrmMainMonographie.aspx?Id=4a7e55ac-b11f-4d80-96d0-b468ab0eb4e3&lang=de&MonType=fi&start=1 |archive-date=29 May 2019 |url-status=dead}}{{Cite web|url=http://www.meppo.com/pdf/drugs/859-GYNODIAN-DEPOT-1440663828.pdf | archive-url = https://web.archive.org/web/20190508150613/http://www.meppo.com/pdf/drugs/859-GYNODIAN-DEPOT-1440663828.pdf | archive-date = 8 May 2019 |title = Gynodian® Depot | publisher = Bayer Middle East | via = HCP MEPPO (Modern Medicine) }}{{cite web |url=http://www.sukl.cz/download/pil/PI23959.pdf |title=Gynodian Depot | language = cs | location = Berlin | publisher = Bayer Pharma AG | date = 31 October 2011 | via = www.sukl.cz |access-date=15 January 2022 |archive-url=https://web.archive.org/web/20190529041214/http://www.sukl.cz/download/pil/PI23959.pdf |archive-date=29 May 2019 |url-status=dead}}{{cite journal | vauthors = Picha E, Weghaupt K | title = [Experience with a new hormone combination for menopausal disorders] | language = de | journal = Medizinische Klinik | volume = 67 | issue = 11 | pages = 382–386 | date = March 1972 | pmid = 4259772 | trans-title = Experience with a new hormone combination for menopausal disorders | quote = A new hormone combination for menopausal complaints. Since the treatment of menopausal complaints with estrogens as well as with the combination of estrogens and androgens causes undesired side effects such as bleeding, mammary changes and masculinisation, dehydroepiandrosteron (DHEA), a precursor of testosteron, has been synthesised, which has only a low conversion rate to free testosteron and no masculinising effect. The substance has been tested in combination with estrogen (200 mg DHEA-enanthate and 4 mg estradiolvalerianate per 1 ml) in 266 women with menopausal complaints. The duration of treatment has been up to 6 years with an injection interval of 3 to 8 weeks. The therapeutic results were as good as with estrogen-androgen-combinations, but there was no masculinising effect. Changes of voice, hair and libido caused by pretreatment partly disappeared. Side effects [such] as acne, mastodynia, and sensation of repletion were of transitory nature. This preparation seems to be a true alternative to the traditional estrogen-androgen-combinations. }}{{cite journal | vauthors = Lauritzen C | title = Erfahrungen in der Behandlung klimakterischer Beschwerden mit Depot-Injektionen von Östradiolvalerianat-Dehydroepiandrosteronönanthat | trans-title = Experience of treatment of climacteric symptoms with depot injections of estradiol valerianate-dehydroandrosterone enantate | journal = Die Therapiewoche | year = 1980 | volume = 30 | issue = 10 | pages = 1736–1742 | issn = 0040-5973 | url = https://scholar.google.com/scholar?cluster=4876387720777135191 | quote = A trial of estradiol valerianate-dehydroandrosterone oenantate (Gynodian-Depot) was conducted in 68 post-menopausal women. The treatment exerted a very favorable influence on the typical subjective disorders of the climacteric and on the atrophic alterations of the target organs. Owing to its estrogenic and dehydroepiandrosterone components, the compound also exerts a favorable psychotropic effect. It was tolerated well and caused no side effects of any significance.}}{{cite journal | vauthors = Jurczok F | title = [Treatment of the climacteric symptom complex with a new combined hormone preparation] | language = de | journal = Fortschritte der Medizin | volume = 94 | issue = 9 | pages = 524–527 | date = March 1976 | pmid = 134967 | trans-title = Treatment of the climacteric symptom complex with a new combined hormone preparation }}{{cite journal | vauthors = Dinulović D, Radonjić G | title = [Gynodian-depot in the treatment of castration-induced postmenopause] | language = hr | journal = Jugoslavenska Ginekologija I Perinatologija | volume = 27 | issue = 1–2 | pages = 37–40 | date = 1987 | pmid = 2960859 | trans-title = Gynodian-depot in the treatment of castration-induced postmenopause }}{{cite journal | vauthors = Düsterberg B, Wendt H | title = Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women | journal = Hormone Research | volume = 17 | issue = 2 | pages = 84–89 | date = 1983 | pmid = 6220949 | doi = 10.1159/000179680 }} It is provided in the form of 1 mL ampoules containing 4 mg estradiol valerate and 200 mg prasterone enanthate in an oil solution and is administered by intramuscular injection once every 4 to 6 weeks. EV/DHEA-E reportedly has a duration of about 21 days.{{cite book | vauthors = Ufer J | title = Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis | trans-title = Hormone Therapy in Gynecology: Principles and Practice | edition = 5th | language = de | date = 1 January 1978 | isbn = 978-3-11-006664-7 | oclc = 924728827 | publisher = de Gruyter | page = 276}}

The medication is available in Europe, Latin America, and Egypt.{{Cite web|url=https://www.drugs.com/international/prasterone.html|title=Prasterone (Dehydroepiandrosterone, DHEA) vaginal Uses, Side Effects & Warnings}}{{cite book | veditors = Sweetman SC | chapter = Sex hormones and their modulators | title = Martindale: The Complete Drug Reference | edition = 36th | year = 2009 | pages = 2100, 2124–2125 | publisher = Pharmaceutical Press | location = London | isbn = 978-0-85369-840-1}}{{cite web |url=https://www.micromedexsolutions.com/ |title=Home |website=micromedexsolutions.com}}{{cite book | vauthors = Muller MF, Dessing RP |title=European Drug Index: European Drug Registrations | edition = Fourth|url=https://books.google.com/books?id=2HBPHmclMWIC&pg=PA566|date=19 June 1998|publisher=CRC Press|isbn=978-3-7692-2114-5|pages=566–567}} EV/DHEA-E was developed and marketed by Schering, was first described in the literature in 1972, and was introduced for medical use in April 1975.{{cite book| vauthors = Sauer F |title=Erfolgsfaktoren für das marktorientierte Management patentgeschützter Arzneimittel: eine Analyse der Produktwahrnehmung niedergelassener Vertragsärzte unter der Berücksichtigung unsicherer Therapieergebnisse|url=https://books.google.com/books?id=C9k9qsEyTaMC&pg=PA37|date=February 2008|publisher=BoD – Books on Demand|isbn=978-3-936863-12-3|pages=37,346}}{{cite book| vauthors = Kaufmann M, Costa SD, Scharl A |title=Die Gynäkologie|url=https://books.google.com/books?id=1pwiBgAAQBAJ&pg=PA917|date=27 November 2013|publisher=Springer-Verlag|isbn=978-3-662-11496-4|pages=917–}}{{cite book| vauthors = Kleemann A, Engel J, Kutscher B, Reichert D |title=Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs|url=https://books.google.com/books?id=fO2IAwAAQBAJ&pg=PT2441|date=14 May 2014|publisher=Thieme|isbn=978-3-13-179525-0|pages=1172–1174, 2441–2442}}

{{Androgen replacement therapy formulations and dosages used in women}}

File:Estradiol and dehydroepiandrosterone levels after a single intramuscular injection of Gynodian Depot in women.png | location = Stuttgart, Germany | language = de | isbn = 978-3137008019 | page = 122}}{{cite journal | vauthors = Rauramo L, Punnonen R, Kaihola LH, Grönroos M | title = Serum oestrone, oestradiol and oestriol concentrations in castrated women during intramuscular oestradiol valerate and oestradiolbenzoate-oestradiolphenylpropionate therapy | journal = Maturitas | volume = 2 | issue = 1 | pages = 53–58 | date = January 1980 | pmid = 7402086 | doi = 10.1016/0378-5122(80)90060-2 }}]]{{Clear}}